▶주메뉴 바로가기
▶본문 바로가기
Sartorius, a German life sciences company with 170 years of history, announced on Nov. 12 that it will invest $100 million in Korea’s bio cluster of Songdo in Incheon to build a manufacturing facility for biologics plant parts. Sartorius’ decision is largely attributable to Korea&rsq...
Biopharmaceutical firm Samsung Biologics unveiled its first research and development center for contract development in the biotechnology hub in southern San Francisco on Thursday. The contract development organization is designed to serve clients -- mostly biopharmaceutical firms there -- to offer...
Enzychem Lifesciences’ COVID-19 treatment candidate EC-18 was granted by the US’ Food and Drug Administration to carry out phase 2 clinical trial on confirmed patients, the company said on August 7. In this phase 2 clinical trial, Enzychem Lifesciences will confirm the therapeutic eff...
GC Pharma on July 29 sought the Drug Ministry’s approval to carry out a phase 2 clinical trials of its plasma-derived COVID-19 treatment. The company plans to conduct tests of its GC5131A on 60 patients at Samsung Medical Center, Asan Medical Center, Chung-Ang University Hospital, Korea Uni...
SK Group is pushing for another initial public offering of its health care affiliate SK Bioscience, just a month after SK Biopharmaceuticals’ record-breaking stock market entry last month. SK Bioscience, a vaccine developer that was spun-off from SK Chemical in July 2018, will reportedly f...
South Korean biopharma giant Celltrion said on July 24 it has launched phase 1 clinical trials of a potential antiviral antibody treatment for COVID-19 patients. The clinical study follows promising preclinical results for the virus treatment candidate and has received approval from the Korean...
Seegene, a Korean diagnostics company acclaimed for having preemptively developed COVID-19 test kits before the pandemic even reached Korea, has since risen to the second rank on the Kosdaq bourse. The ongoing coronavirus threat has shifted the market positions of companies across industries, wi...
We know this by many names. Poo, feces, stool, turd, excrement. ... The list can grow endless if imaginative children join in. But scatology is not a matter to be lightly regarded, as “gut feelings” take on a literal meaning in health care. Chunlab, a microbiome research firm, on Tues...
SK Biopharmaceuticals, a drug company researching and developing novel medicines for central nervous system disorders, is set to make a record-breaking initial public offering. On June 24, the second and final day of the company’s subscription-open for individual investors, the proof of mea...
South Korean drug developer SK Biopharmaceuticals is likely to get an early admission to join the Kospi 200 -- a basket of top 200 blue-chip stocks of the nation’s benchmark index Kospi -- possibly only two months after its planned market debut in July, according to local analysts on June 22. ...
Biologics drug developer Celltrion said Wednesday it will accelerate its insulin pen biosimilar development along with medical device manufacturer Poonglim Pharmatech. Celltrion will begin developing the insulin biosimilar this year with aims to commercially launch the product in 2025. ...
Samsung Biologics has bagged two contract manufacturing deals worth 468 billion won ($378 million) combined, according to its regulatory filing on May 22. The total value of the latest deals is equal to two-thirds of the company’s revenue for last year at 701 billion won. According to ...
Macrogen, a genomics biotech company, announced Thursday that its AxenTM Covid-19 RT test kit has gained the Drug Ministry’s approval for export. “We are planning to supply our test kit to major countries, which contacted us even during the test kit development phase and were looking...
SK Pharmteco, a consolidated global pharmaceuticals manufacturing chain of SK Group, will provide US-based Phlow with pharmaceutical ingredients to offset supply shortfall in the country, SK Holdings announced on May 20. The Donald Trump administration has announced it will buttress the project w...
DongKoo Bio&Pharma said on May 19 that it has expanded its field of business to artificial intelligence by investing 3 billion won ($2.4 million) in medical solution provider Vuno. The two firms signed a memorandum of understanding whereby DongKoo Bio&Pharma will leverage its 50-year know-h...
Seoul shares rattled by Israeli attack on Iran; Kospi dips to nearly 11-week low
S-Oil donates W560m to support firefighters
LG CNS teams up with Yonsei University to nurture AI specialists
Polestar 4 to make Korean debut in June
S. Korea pledges W23tr venture capital fund for green investment at G20 meeting
Sungsimdang outperforms bakery giants to log sales over W100b